Do Semaglutide Tablets Work? What the Trial Evidence Shows

The OASIS 4 trial: where the weight-loss numbers come from

The evidence base for oral semaglutide as a weight-loss medicine starts with the OASIS 4 phase-3 trial, 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, followed for 64 weeks. Participants took once-daily semaglutide tablets alongside lifestyle changes. The result was an average weight loss of around 13.6% in the active group versus roughly 2.4% in the placebo group, as reported in Novo Nordisk's announcement around the MHRA's June 2026 approval. That difference is not trivial. Reductions of 5–10% of body weight are consistently associated with clinically meaningful improvements in blood pressure, cholesterol and blood-glucose regulation in the medical literature.

One misconception worth addressing gently: some people read the 16.6% figure for fully adherent participants and assume that is the typical outcome. It is not, it reflects those who took every dose correctly across the whole trial. The 13.6% average, which includes everyone regardless of adherence, is the more honest benchmark for most people thinking about starting treatment. Both figures are real; they just answer different questions. You can read more about the results people see in practice in our dedicated results page.

Gastrointestinal side effects were common in the trial, reported by around 74% of participants on semaglutide compared with 42% on placebo. Most were mild to moderate and settled over time, particularly after dose increases. This is consistent with what is seen across the wider semaglutide class, and it is part of why the dose is stepped up gradually rather than started at the maintenance level.

How the tablet is absorbed, and why the morning routine matters

Understanding how semaglutide tablets work requires knowing something about their absorption. Semaglutide is a peptide, which ordinarily would be broken down in the stomach before reaching the bloodstream. The tablet gets around this by pairing semaglutide with an absorption enhancer called SNAC, which temporarily alters the local stomach environment to allow absorption through the gastric wall. That mechanism is well established for this molecule, though bioavailability is significantly lower than the injection.

The practical implication is that the tablet must be taken on a genuinely empty stomach (first thing in the morning, with no more than a small sip of plain water) and nothing else, including coffee, should be consumed for at least 30 minutes afterwards. Other oral medicines should also wait that same window. This is not a minor lifestyle note; it is the condition under which the medicine's absorption was tested and licensed. Our guide to how oral semaglutide works goes into the SNAC mechanism in more detail if you want the fuller picture.

The no-refrigeration point is genuinely useful here. The injection version of Wegovy needs to be kept at 2–8°C until use, which introduces storage complexity. The tablet sits at room temperature, travels easily, and fits more naturally into a morning routine. For people who find needles an obstacle, the tablet removes that barrier entirely, though the absorption requirements introduce a different kind of discipline.

Who the tablets are licensed for, and what the prescriber weighs up

The MHRA licensed Wegovy tablets for adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea, alongside a reduced-calorie diet and increased physical activity. The NHS has not yet made oral semaglutide available through the health service (a NICE appraisal would need to happen first) so currently it is available through private prescription only. The Wegovy tablet overview covers the full licensing picture if you are weighing up your options.

A prescriber reviewing your suitability will look at more than your BMI. Contraindications, other medicines you take, your history with GI conditions, and whether you have previously tried injectable semaglutide all matter. People who are already established on the 2.4 mg weekly injection may, subject to clinical assessment, move directly to the 25 mg tablet rather than restarting from the lowest dose. The evidence on oral semaglutide broadly is worth reading if you are comparing your options, and our treatment costs page sets out what private access typically involves.

Pregnancy and breastfeeding are contraindications, oral semaglutide is not recommended for anyone who is pregnant, breastfeeding, or actively trying to conceive, and it is not licensed for under-18s. These are clinical decisions, not administrative ones, which is exactly why assessment by a real prescriber matters at the outset. The molecular background on semaglutide may be useful reading if you want context on the science before a consultation.

What the evidence does not answer on its own

Trial data tells you what happened on average, in a controlled setting, over a defined period. It cannot tell you how semaglutide tablets will work for you specifically, because your metabolism, medical history, other medications and daily context are all different from the average trial participant. That gap is exactly what clinical assessment exists to bridge. A prescriber can help you interpret the evidence in light of your situation, set realistic expectations, and monitor how you respond over time. The NHS medicines page for semaglutide offers plain-English guidance on the medicine class as a whole, and is worth reading alongside any commercial information.

One practical note: the dose stepping schedule takes several months to reach the 25 mg maintenance level, 1.5 mg, then 4 mg, then 9 mg, with at least a month at each stage. Early weeks are about letting your system adjust, and noticeable weight change typically becomes more consistent once you are closer to the maintenance dose. Patience with the process is not a cliché; it is reflected in how the trial was designed. Our general weight-loss treatment overview gives a broader view of how this fits alongside other licensed options, and you are welcome to explore our frequently asked questions if anything here raises further queries. When you are ready to discuss your situation with a prescriber, starting a free consultation is the natural next step.